Hypoglycemia-associated autonomic failure in diabetes

Handbook of Clinical Neurology

Volumn 117, Issue , 2013, Pages 295-307

  Cryer, Philip E ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

Adrenal Medulla; Diabetes); Epinephrine; Glucagon; Hypoglycemia Associated Autonomic Failure; Insulin; Sympathetic Nervous System (Hypoglycemia; Sympathoadrenal System

Indexed keywords

ADRENALIN; GLUCAGON; INSULIN;

ADRENAL MEDULLA; ADRENERGIC SYSTEM; ARTICLE; AUTONOMIC NEUROPATHY; DIABETES MELLITUS; DIABETES); HUMAN; HYPOGLYCEMIA; HYPOGLYCEMIA-ASSOCIATED AUTONOMIC FAILURE; PATHOLOGY; SYMPATHETIC NERVOUS SYSTEM (HYPOGLYCEMIA;

ADRENAL MEDULLA; DIABETES); EPINEPHRINE; GLUCAGON; HYPOGLYCEMIA-ASSOCIATED AUTONOMIC FAILURE; INSULIN; SYMPATHETIC NERVOUS SYSTEM (HYPOGLYCEMIA; SYMPATHOADRENAL SYSTEM;

AUTONOMIC NERVOUS SYSTEM DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA;

EID: 84884945765     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53491-0.00023-7     Document Type: Chapter

References (84)

1. Action to Control Cardiovascular Risk in Diabetes Study Group ACCORD Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
2. Adler G.K., Bonyhay I., Failing H., et al. Antecedent hypoglycemia impairs autonomic cardiovascular function. Implications for rigorous glycemic control. Diabetes 2009, 58:360-366.
3. American Diabetes Association Workgroup on Hypoglycemia Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005, 28:1245-1249.
4. Arbelaez A.M., Powers W.J., Videen T.O., et al. Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes 2008, 57:470-475.
5. Banarer S., McGregor V.P., Cryer P.E. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 2002, 51:958-965.
6. Bolli G.B., De Feo P., De Cosmo S., et al. A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. Diabetes 1984, 33:732-737.
7. Bonadonna R.C., Heise T., Arbet-Engels C., et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010, 95:5028-5036.
8. Cooke D., Hurel S.J., Casbardt A., et al. Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA(1c) in insulin-treated diabetes (MITRE Study). Diabet Med 2009, 26:540-547.
9. Cooperberg B.A., Cryer P.E. Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans. Diabetes Care 2009, 32:2275-2280.
10. Cooperberg B.A., Cryer P.E. Insulin reciprocally regulates glucagon secretion in humans. Diabetes 2010, 59:2936-2940.
11. Cranston I., Lomas J., Maran A., et al. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994, 344:283-287.
12. Cryer P.E. The prevention and correction of hypoglycemia (Ch. 35). The Endocrine Pancreas and Regulation of Metabolism 2001, Vol. II:1057-1092. Oxford University Press, New York. H.M. Goodman (Ed.).
13. Cryer P.E. Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. J Clin Invest 2006, 116:1470-1473.
14. Cryer P.E. Hypoglycemia, functional brain failure, and brain death. J Clin Invest 2007, 117:868-870.
15. Cryer P.E. The barrier of hypoglycemia in diabetes. Diabetes 2008, 57:3169-3176.
16. Cryer P.E. Hypoglycemia in Diabetes. Pathophysiology, Prevalence and Prevention 2009, American Diabetes Association, Alexandria, VA.
17. Cryer P.E. Preventing hypoglycaemia: what is the appropriate glucose alert value?. Diabetologia 2009, 52:35-37.
18. Cryer P.E. Elimination of hypoglycemia from the lives of people affected by diabetes. Diabetes 2011, 60:24-27.
19. Currie C.J., Peters J.R., Tynan A., et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489.
20. Dagogo-Jack S.E., Craft S., Cryer P.E. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993, 91:819-828.
21. Dagogo-Jack S., Rattarasarn C., Cryer P.E. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994, 43:1426-1434.
22. de Galan B.E., Tack C.J., Willemsen J.J., et al. Plasma metanephrine levels are decreased in type 1 diabetic patients with a severely impaired epinephrine response to hypoglycemia, indicating reduced adrenomedullary stores of epinephrine. J Clin Endocrinol Metab 2004, 89:2057-2061.
23. DeRosa M.A., Cryer P.E. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab 2004, 287:E32-E41.
24. Diabetes Control and Complications Trial Research Group (DCCT) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
25. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
26. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007, 356:1842-1852.
27. Diem P., Redmon J.B., Abid M., et al. Glucagon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. J Clin Invest 1990, 86:2008-2013.
28. Donnelly L.A., Morris A.D., Frier B.M., et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005, 22:749-755.
29. Fanelli C.G., Epifano L., Rambotti A.M., et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993, 42:1683-1689.
30. Fanelli C., Epifano L., Rambotti A.M., et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994, 37:1265-1276.
31. Feltbower R.G., Bodansky H.J., Patterson C.C., et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of Diabetes in Children and Young Adults. Diabetes Care 2008, 31:922-926.
32. Ferner R.E., Neil H.A. Sulphonylureas and hypoglycaemia. Br Med J (Clin Res Ed) 1988, 296:949-950.
33. Ferrannini E., Ramos S.J., Salsali A., et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010, 33:2217-2224.
34. Geddes J., Schopman J.E., Zammitt N.N., et al. Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med 2008, 25:501-504.
35. Gerich J.E. Oral hypoglycemic agents. N Engl J Med 1989, 321:1231-1245.
36. Gerich J.E., Charles M.A., Grodsky G.M. Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. J Clin Invest 1974, 54:833-841.
37. Gill G.V., Woodward A., Casson I.F., et al. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes - the "dead in bed" syndrome revisited. Diabetologia 2009, 52:42-45.
38. Goldstein D.S., Kopin I.J. Adrenomedullary, adrenocortical, and sympathoneural responses to stressors: a meta-analysis. Endocr Regul 2008, 42:111-119.
39. Gosmanov N.R., Szoke E., Israelian Z., et al. Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care 2005, 28:1124-1131.
40. Heller S.R., Cryer P.E. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991, 40:223-226.
41. Hepburn D.A., MacLeod K.M., Pell A.C., et al. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 1993, 10:231-237.
42. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
43. Holstein A., Egberts E.H. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2003, 111:405-414.
44. International Diabetes Federation IDF Diabetes Atlas 2009, International Diabetes Federation, Brussels, Belgium. 4th edn.
45. Israelian Z., Gosmanov N.R., Szoke E., et al. Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes. Diabetes Care 2005, 28:2691-2696.
46. Jaferi A., Bhatnagar S. Corticosterone can act at the posterior paraventricular thalamus to inhibit hypothalamic-pituitary-adrenal activity in animals that habituate to repeated stress. Endocrinology 2006, 147:4917-4930.
47. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008, 359:1464-1476.
48. Lachin J.M., Genuth S., Nathan D.M., et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial - revisited. Diabetes 2008, 57:995-1001.
49. C interval and QT dispersion in man. Eur J Clin Invest 2003, 33:93-98.
50. Lee S.P., Harris N.D., Robinson R.T., et al. Effect of atenolol on QTc interval lengthening during hypoglycaemia in type 1 diabetes. Diabetologia 2005, 48:1269-1272.
51. ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol 2007, 5:e143.
52. McCrimmon R.J., Sherwin R.S. Hypoglycemia in type 1 diabetes. Diabetes 2010, 59:2333-2339.
53. Murphy N.P., Ford-Adams M.E., Ong K.K., et al. Prolonged cardiac repolarisation during spontaneous nocturnal hypoglycaemia in children and adolescents with type 1 diabetes. Diabetologia 2004, 47:1940-1947.
54. NICE-SUGAR Study Investigators, Finfer S., Chittock D.R., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283-1297.
55. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010, 53:1552-1561.
56. Paramore D.S., Fanelli C.G., Shah S.D., et al. Forearm norepinephrine spillover during standing, hyperinsulinemia, and hypoglycemia. Am J Physiol 1998, 275:E872-E881.
57. Paranjape S.A., Chan O., Zhu W., et al. Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo. Diabetes 2010, 59:1521-1527.
58. Pedersen-Bjergaard U., Pramming S., Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 2003, 19:232-240.
59. Phung O.J., Scholle J.M., Talwar M., et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
60. Pogach L., Aron D. Balancing hypoglycemia and glycemic control: a public health approach for insulin safety. JAMA 2010, 303:2076-2077.
61. Puente E.C., Silverstein J., Bree A.J., et al. Recurrent moderate hypoglycemia ameliorates brain damage and cognitive dysfunction induced by severe hypoglycemia. Diabetes 2010, 59:1055-1062.
62. Raju B., Cryer P.E. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes 2005, 54:757-764.
63. Reichard P., Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994, 43:313-317.
64. Robinson R.T., Harris N.D., Ireland R.H., et al. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes 2003, 52:1469-1474.
65. Robinson R.T., Harris N.D., Ireland R.H., et al. Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with type 1 diabetes. Diabetologia 2004, 47:312-315.
66. Ryder R.E., Owens D.R., Hayes T.M., et al. Unawareness of hypoglycaemia and inadequate hypoglycaemic counterregulation: no causal relation with diabetic autonomic neuropathy. BMJ 1990, 301:783-787.
67. Schernthaner G. Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010, 160:8-19.
68. Schopman J.E., Geddes J., Frier B.M. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin Pract 2010, 87:64-68.
69. Segel S.A., Paramore D.S., Cryer P.E. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002, 51:724-733.
70. Sherck S.M., Shiota M., Saccomando J., et al. Pancreatic response to mild non-insulin-induced hypoglycemia does not involve extrinsic neural input. Diabetes 2001, 50:2487-2496.
71. Sjöbom N.C., Adamson U., Lin P.E. The prevalence of impaired glucose counter-regulation during an insulin-infusion test in insulin-treated diabetic patients prone to severe hypoglycaemia. Diabetologia 1989, 32:818-825.
72. Skrivarhaug T., Bangstad H.J., Stene L.C., et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006, 49:298-305.
73. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Diabetes Care 2009, 32:187-192.
74. Taborsky G.J., Mei Q., Hackney D.J., et al. Loss of islet sympathetic nerves and impairment of glucagon secretion in the NOD mouse: relationship to invasive insulitis. Diabetologia 2009, 52:2602-2611.
75. Tanenberg R.J., Newton C.A., Drake A.J. Confirmation of hypoglycemia in the "dead-in-bed" syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract 2010, 16:244-248.
76. Tesfaye S., Boulton A.J., Dyck P., et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010, 33:2285-2293.
77. Teves D., Videen T.O., Cryer P.E., et al. Activation of human medial prefrontal cortex during autonomic responses to hypoglycemia. Proc Natl Acad Sci U S A 2004, 101:6217-6221.
78. Towler D.A., Havlin C.E., Craft S., et al. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 1993, 42:1791-1798.
79. UK Hypoglycaemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007, 50:1140-1147.
80. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
81. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
82. UK Prospective Diabetes Study (UKPDS) Group United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998, 128:165-175.
83. White N.H., Skor D.A., Cryer P.E., et al. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 1983, 308:485-491.
84. Yudkin J.S., Richter B., Gale E.A. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010, 53:2079-2085.